Stoke Therapeutics, Inc. $STOK Shares Bought by KLP Kapitalforvaltning AS

Key Points

• KLP Kapitalforvaltning AS increased its stake in Stoke Therapeutics by 131.6%, acquiring an additional 7,500 shares in the 2nd quarter, bringing its total holdings to 13,200 shares worth approximately $150,000.
• Equities research analysts have raised price targets for Stoke Therapeutics, with BTIG Research increasing its target from $28.00 to $39.00, while Weiss Ratings maintains a "sell (d+)" rating.
• Stoke Therapeutics reported earnings of ($0.40) per share for the last quarter, exceeding estimates, but revenue fell short at $13.82 million against anticipated $31.51 million.

KLP Kapitalforvaltning AS increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 131.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,200 shares of the company's stock after purchasing an additional 7,500 shares during the period. KLP Kapitalforvaltning AS's holdings in Stoke Therapeutics were worth $150,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of STOK. Wellington Management Group LLP lifted its stake in shares of Stoke Therapeutics by 0.9% during the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock valued at $904,000 after buying an additional 1,148 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after acquiring an additional 1,149 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after acquiring an additional 5,084 shares in the last quarter. MPM Bioimpact LLC grew its holdings in Stoke Therapeutics by 1.2% during the 1st quarter. MPM Bioimpact LLC now owns 693,988 shares of the company's stock valued at $4,615,000 after purchasing an additional 8,162 shares in the last quarter. Finally, AlphaQuest LLC acquired a new stake in Stoke Therapeutics during the 1st quarter valued at $72,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. BTIG Research raised their price target on shares of Stoke Therapeutics from $28.00 to $39.00 and gave the company a "buy" rating in a report on Monday, October 13th. Chardan Capital restated a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Stoke Therapeutics in a research report on Wednesday, October 8th. Wedbush raised their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. Finally, Needham & Company LLC lifted their price objective on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $30.83.

Stoke Therapeutics Trading Up 0.1%

Shares of STOK stock opened at $34.68 on Wednesday. The firm has a market capitalization of $1.90 billion, a P/E ratio of 40.80 and a beta of 1.24. The firm's fifty day simple moving average is $23.89 and its 200 day simple moving average is $15.20. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. The firm had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. Equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Barry Ticho sold 5,501 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total transaction of $109,304.87. Following the transaction, the insider owned 18,469 shares in the company, valued at $366,979.03. This represents a 22.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jonathan Allan sold 10,000 shares of the company's stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $25.07, for a total transaction of $250,700.00. Following the transaction, the general counsel owned 11,831 shares in the company, valued at approximately $296,603.17. This trade represents a 45.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold 185,180 shares of company stock worth $4,129,406 in the last quarter. 9.50% of the stock is owned by corporate insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.